Director, ADME, PK

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients.

We are seeking a highly motivated individual to join Turning Point Therapeutics as a Director, ADME/PK . The Director of ADME/PK will be involved in the design, execution, analysis, interpretation and communication of nonclinical ADME/PK studies of small molecule and their associated delivery system to provide nonclinical ADME/PK profiles and risk assessment to support drug development. This position requires strong intellectual leadership, working at the interface of discovery and development teams and will serve as the nonclinical subject matter expert. The incumbent will design, conduct, and interpret nonclinical ADME/PK and investigational studies; will advise management on the pharmacokinetic aspects of the project and will effectively communicate with worldwide regulatory agencies to bring our drugs to patients as quickly as possible. This is an ideal position for an independent individual with a strong background in discovery and preclinical ADME/PK who enjoys working in a team-oriented and highly cross-disciplinary environment.

 Responsibilities:

• Design, plan, monitor and conduct nonclinical ADME/pharmacokinetic studies to support drug candidate nomination and through the lifecycle of small molecule candidates in-house and at contract research organizations.
• Interpret ADME/ pharmacokinetic data to inform the design of pharmacology and toxicology studies.
• Interpret pharmacokinetic data to inform human dose projections.
• Conduct or be accountable for PKPD modeling activities to estimate efficacious dose and exposure range in humans along with therapeutics margins for nonclinical studies.
• Serve on research project teams as preclinical pharmacokinetics representative.
• Collaborate closely with bioanalytical scientists and toxicologists.
• Draft nonclinical pharmacokinetic sections of regulatory documents.